Search clinical trials for: Reduced intensity conditioning

Total 5427 results

Masonic Cancer Center, University of Minnesota

Recruiting

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

Acquired Pure Red Cell Aplasia | Paroxysmal Nocturnal Hemoglobinuria | Severe Aplastic Anemia | Acquired Amegakaryocytic Thrombocytopenia

United States
Nantes University Hospital

Recruiting

Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT (FLUCLORIC)

Acute Myeloid Leukemia in Remission

France
Shanghai Jiao Tong University School of Medicine

Recruiting

Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia

Refractory Leukemia

China
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia

Recurrent Severe Aplastic Anemia | Refractory Severe Aplastic Anemia

United States
Wuhan Union Hospital, China

Recruiting

Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome

Allogeneic Hematopoietic Stem Cell Transplantation | Acute Myeloid Leukemia, Adult | Myelodysplastic Syndrome(MDS)

China
Ossium Health, Inc.
Center for International Blood and Marrow Transplant Research

Recruiting

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Acute Leukemia | Acute Undifferentiated Leukemia | Acute Biphenotypic Leukemia

United States
TScan Therapeutics, Inc.

Recruiting

A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation

Myelodysplastic Syndromes | AML | ALL, Adult

United States
National Cancer Institute (NCI)

Recruiting

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Hematopoietic Stem Cell Transplantation | Peripheral Blood Stem Cell Transplantation

United States
University of California, Los Angeles

Recruiting

Autologous Mobilized Peripheral Blood CD34+ Hematopoietic Stem and Progenitor Cells (HSPC) Transduced With the Elongation Factor Alpha Short Promoter (EFS) - Adenosine Deaminase (ADA) Gene (EFS-ADA) Lentiviral Vector for Adenosine Deaminase Severe Combined Immune Deficiency (ADA SCID)

Adenosine Deaminase Severe Combined Immune Deficiency

United States
Stanford University
Orca Biosystems, Inc.

Recruiting

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Myelodysplastic Syndromes | Myeloproliferative Disorders | Acute Leukemia | Chronic Myelogenous Leukemia | Allogeneic Hematopoietic Cell Transplantation (HCT) | Advanced Hematologic Malignancies

United States
Thomas Jefferson University

Recruiting

Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myeloid Leukemia | Polycythemia Vera | Essential Thrombocythemia | Hodgkin Lymphoma | Myelofibrosis | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma and other conditions

United States
Melbourne Health

Recruiting

Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation (VICTORY)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Plasma Cell Myeloma | Non-hodgkin Lymphoma | Leukemia, Lymphoblastic, Acute, L1 | Leukemia, Lymphoblastic, Acute, L2

Australia
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Recruiting

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic Syndrome | Refractory Mixed Phenotype Acute Leukemia | Refractory Acute Leukemia... and other conditions

United States
Washington University School of Medicine

Recruiting

Vigabatrin and Insulin Sensitivity

Obesity | NAFLD

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Not yet recruiting

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

Metastatic Sarcoma | Resectable Sarcoma | Recurrent Sarcoma

United States
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Comparison of Allogeneic Matched Related Haematopoietic Stem Cell Transplantation After a Reduced Intensity Conditioning Regimen With Standard of Care in Adolescents and Adults With Severe Sickle Cell Disease (DREPA-RIC)

Sickle Cell Disease
University of Liege
Belgian Hematological Society

Recruiting

Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning (HLA)

Myelodysplastic Syndromes | Multiple Myeloma | Hodgkin Lymphoma | Non Hodgkin Lymphoma | Myeloproliferative Disorder | Chronic Lymphoid Leukemia | Acute Myeloid Leukemia in Remission | Myeloproliferative Syndrome | Chronic Myeloid Leukemia in Remission | Acute Lymphoid Leukemia in Remission

Belgium
National Cancer Institute (NCI)

Recruiting

Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation

Immune System Diseases | Lymphoproliferative Disorders | Common Variable Immunodeficiency | Primary T-cell Immunodeficiency Disorders | Autoimmune Lymphoproliferative

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Institutes of Health (NIH)

Recruiting

Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

Diffuse Large B-Cell Lymphoma | Acute Myeloid Leukemia | Recurrent Hodgkin Lymphoma | Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Myelodysplastic Syndrome | Recurrent Small Lymphocytic Lymphoma | Blastic Plasmacytoid Dendritic Cell Neoplasm | Prolymphocytic Leukemia and other conditions

United States
Medical College of Wisconsin

Recruiting

Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation

Multiple Myeloma | Hematological Malignancy

United States
Washington University School of Medicine

Recruiting

Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

Hemoglobinopathies | Bone Marrow Failure Syndromes | Metabolic Disorders | Non-malignant Disorders | Severe Sickle Cell Disease | Immunologic Disorders

United States
National Cancer Institute (NCI)

Recruiting

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies

Immune System Diseases | Lymphoproliferative Disorders | Common Variable Immunodeficiency | Primary T-cell Immunodeficiency Disorders | Autoimmune Lymphoproliferative

United States
Paul Szabolcs

Recruiting

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT (HSCT+RIC)

Congenital Bone Marrow Failure Syndromes | Inflammatory Conditions | Primary Immunodeficiency (PID) | Inherited Metabolic Disorders (IMD) | Hereditary Anemias | Systemic Juvenile Idiopathic Arthritis (sJIA)

United States
Masonic Cancer Center, University of Minnesota

Recruiting

Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

Hemoglobinopathies | Immunodeficiencies | Hematologic Disorders

United States
Diane George

Active, not recruiting

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

Acute Lymphoblastic Leukemia (ALL) | Myelodysplastic Syndrome (MDS) | Acute Myelogenous Leukemia (AML) | Chronic Myeloid Leukemia (CML) | Juvenile Myelomonocytic Leukemia (JMML) | Lymphoma (Hodgkin's and Non-Hodgkin's)

United States
University of Birmingham

Active, not recruiting

A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC) (ALL-RIC)

Acute Lymphoblastic Leukemia

United Kingdom
University of Liege
University Hospital, Gasthuisberg; University Hospital, Ghent; University Hospital... and other collaborators

Active, not recruiting

Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens

Hematological Malignancies | Graft-Versus-Host Disease

Belgium
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Hodgkin Lymphoma | Burkitt Lymphoma | Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Lymphoplasmacytic Lymphoma | Chronic Myelogenous Leukemia | Prolymphocytic Leukemia | Myeloproliferative Neoplasm | Relapsed Follicular Lymphoma | Relapsed T-Cell Lymphoma and other conditions

United States
Polish Lymphoma Research Group
AstraZeneca

Active, not recruiting

Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) (ACALLO)

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Adverse Event | Chronic Graft-versus-host-disease | Response Rate

Poland
Monica Thakar

Completed

Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors (STIR)

Osteosarcoma | Ewing Sarcoma | Neuroblastoma | Rhabdomyosarcoma | CNS Tumors

United States
Children's Hospital of Philadelphia

Active, not recruiting

Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders (RIC)

Hemoglobinopathies | Immunodeficiencies | Non Malignant Diseases

United States
European Society for Blood and Marrow Transplantation
Novartis

Completed

Non Interventional Study on Iron Toxicity After First Allo-transplant in MDS/CMML

MDS | CMML

Germany, Belgium, Czechia
Masonic Cancer Center, University of Minnesota

Terminated

Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases

Sickle Cell Disease | Thalassemia | Cerebral Adrenoleukodystrophy | Inherited Metabolic Disorders | High Risk Hematologic Disorders

United States
Boston Children's Hospital
Massachusetts General Hospital; Mayo Clinic; Karolinska University Hospital; Baylor... and other collaborators

Active, not recruiting

Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita

Aplastic Anemia | Dyskeratosis Congenita | Hoyeraal Hreidarsson Syndrome | Revesz Syndrome

United States, Norway, Sweden
Medical College of Wisconsin
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Active, not recruiting

Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)

Sickle Cell Disease

United States
Randy Windreich

Completed

Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS) | Hematopoietic Stem Cell Transplant (HSCT)

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia

Myeloid Diseases

United States
Beth Israel Deaconess Medical Center
Genzyme, a Sanofi Company

Completed

Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Acute Lymphocytic Leukemia | Hodgkins Disease | Relapsed/Refractory Chronic Lymphocytic Leukemia | Relapsed Refractory Multiple Myeloma | Relapsed/Refractory Non Hodgkin's Lymphoma

United States
Dana-Farber Cancer Institute
National Cancer Institute (NCI)

Completed

Development and Piloting an Avatar-based Intervention to Support Patients Undergoing Stem Cell Transplantation

Hematopoietic Cell Transplantation

United States
Catherine Bollard
Children's National Research Institute

Active, not recruiting

Haploidentical Hematopoietic Stem Cell Transplantation

Thalassemia | Sickle Cell-thalassemia Disease

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation

Primary Myelofibrosis | Acute Leukemia | Myelodysplastic Syndrome | Secondary Myelofibrosis | Hematologic and Lymphocytic Disorder

United States
University of Nebraska
National Cancer Institute (NCI)

Withdrawn

Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Nonmalignant Neoplasm

United States
Andrew Rezvani
National Institutes of Health (NIH); Pharmacyclics LLC.

Completed

Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Hematopoietic Cell Transplantation Recipient | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Acute Biphenotypic Leukemia

United States
University of Arizona

Active, not recruiting

Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine

Lymphoma, Follicular | Myelodysplastic Syndromes | Burkitt Lymphoma | Acute Lymphoblastic Leukemia | Marginal Zone Lymphoma | Acute Myelogenous Leukemia | Mantle-Cell Lymphoma | Chronic Myelogenous Leukemia | Lymphoma, Hodgkin | Gray Zone Lymphoma | Lymphoma,Non-Hodgkin | Large Cell Lymphoma | High Risk Undifferentiated...

United States
West Virginia University

Completed

Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene

Confirmed Diagnosis of ß-thalassemia Major

United States
Masonic Cancer Center, University of Minnesota

Active, not recruiting

Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT

Hematologic Malignancies

United States
Northside Hospital, Inc.
Blood and Marrow Transplant Group of Georgia

Completed

Reduced Intensity Conditioning Transplant Using Haploidentical Donors

Multiple Myeloma | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Myelofibrosis | Chronic Lymphocytic Leukemia | Myelodysplastic Syndrome | Acute Lymphocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | CMML

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
National Cancer Institute (NCI)

Completed

Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies

Follicular Lymphoma | Myeloid Leukemia | Polycythemia Vera | Hodgkin Lymphoma | Myelofibrosis | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Chronic Lymphocytic Leukemia | Secondary Acute Myeloid Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Plasma Cell Myeloma | Refractory... and other conditions

United States
Medical College of Wisconsin
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Completed

Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204) (RICHI)

Chronic Granulomatous Disease | Hemophagocytic Lymphohistiocytosis | Leukocyte Adhesion Deficiency | Chronic Active Epstein-Barr Virus Infection | HIGM-1 | IPEX

United States, Canada

Search clinical trials for: Reduced intensity conditioning

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Greece

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations